Published online before print March 9, 2006, doi: 10.1161/01.RES.0000216858.04599.e1
© 2006 American Heart Association, Inc.
Cellular Biology |
Serotonin Inhibits Voltage-Gated K+ Currents in Pulmonary Artery Smooth Muscle Cells
Role of 5-HT2A Receptors, Caveolin-1, and KV1.5 Channel Internalization
From the Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain.
Correspondence to Angel Cogolludo, Department Pharmacology, School Medicine, Universidad Complutense, 28040 Madrid, Spain. E-mail acogolludo{at}ift.csic.es
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Multiple lines of evidence indicate that serotonin (5-hydroxytryptamine [5-HT]) and voltage-gated K+ (KV) channels play a central role in the pathogenesis of pulmonary hypertension (PH). We hypothesized that 5-HT might modulate the activity of KV channels, therefore establishing a link between these pathogenetic factors in PH. Here, we studied the effects of 5-HT on KV channels present in rat pulmonary artery smooth muscle cells (PASMC) and on hKV1.5 channels stably expressed in Ltk– cells. 5-HT reduced native KV and hKV1.5 currents, depolarized cell membrane, and caused a contraction of isolated pulmonary arteries. The effects of 5-HT on KV currents and contraction were markedly prevented by the 5-HT2A receptor antagonist ketanserin. Incubation with inhibitors of phospholipase C (U73122), classic protein kinase Cs (Gö6976), or tyrosine kinases (genistein and tyrphostin 23), the cholesterol depletion agent ß-cyclodextrin or concanavalin A, an inhibitor of endocytotic processes, also prevented the effects of 5-HT. In homogenates from pulmonary arteries, 5-HT2A receptors and caveolin-1 coimmunoprecipitated with KV1.5 channels, and this was increased on stimulation with 5-HT. Moreover, KV1.5 channels were internalized when cells were stimulated with 5-HT, and this was prevented by concanavalin A. These findings indicate that activation of 5-HT2A receptors inhibits native KV and hKV1.5 currents via phospholipase C, protein kinase C, tyrosine kinase, and a caveolae pathway. KV channel inhibition accounts, at least partly, for 5-HT-induced pulmonary vasoconstriction and might play a role in PH.
Key Words: potassium ion channels hypertension • pulmonary arteries • receptors
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Pulmonary hypertension (PH) is a heterogeneous group of disorders characterized by a sustained increase in pulmonary artery (PA) pressure leading to progressive right ventricular failure and death. Several lines of evidence indicate that serotonin (5-hydroxytryptamine [5-HT]) plays a central role in the pathogenesis of PH.1,2 First, 5-HT is an effective pulmonary vasoconstrictor and induces vascular smooth muscle hyperplasia.2–5 Moreover, plasma levels of 5-HT are increased in patients with primary PH.6 Conversely, mild pulmonary hypertension has been reported in some series of patients with carcinoid syndrome, a tumor of enterochromaffin cells releasing large amounts of 5-HT.7 Patients treated with fenfluramine or dexfenfluramine, anorectic drugs that induce platelet 5-HT release, inhibit the 5-HT transporter (5-HTT) and stimulate 5-HT receptors, also have a 23-fold increased risk of PH.8 In addition, 5-HTT overexpression or polymorphisms in the gene encoding the 5-HTT are associated with PH.9,10 Furthermore, mice lacking 5-HTT or 5-HT receptors (eg, 5-HT1B or 5-HT2B) show attenuated PH induced by hypoxia.3,11,12 Finally, specific pharmacological inhibition of 5-HT1B or 5-HT2A receptors or 5-HTT attenuates and/or reverses the development of PH and prolongs survival in animal models of PH.3,12–15
K+ channels play an essential role in regulating resting membrane potential, intracellular calcium concentration ([Ca2+]i), and contraction of vascular smooth muscle.16–18 Activation of K+ channels leads to hyperpolarization, whereas their inhibition causes membrane depolarization, activation of voltage-gated L-type Ca2+ channels, increase in [Ca2+]i, and vasoconstriction. Voltage-gated K+ (KV) channels present in pulmonary artery smooth muscle cells (PASMC) are inhibited by hypoxia, endothelin-1, thromboxane A2, and anorectic drugs.16,19–21 Moreover, decreased expression or function of KV channels in PASMC has been involved in the pathogenesis of primary and anorexigen-induced PH.21,22 From the variety of KV channels expressed in PASMC, special interest has been paid to KV1.5, because decreased expression or activity and mutations of KV1.5 occurs in primary PH22,23 and in vivo gene transfer of KV1.5 reduces PH and restores hypoxic pulmonary vasoconstriction.24 Furthermore, decreased expression and function of KV channels in PASMC leads to inhibition of apoptosis and promotes pulmonary vascular medial hypertrophy,25 whereas upregulation of KV1.5 correlates with an increase in apoptosis/proliferation ratio and prevents and reverses PH.26
As stated above, both 5-HT and KV channels may have an etiological role in PH. Unfortunately, the effects of 5-HT on KV channels in PASMC have not been analyzed yet. We hypothesized that 5-HT might inhibit KV channels, thereby establishing a link between these 2 pathogenic pathways in PH. Therefore, in the present study we have analyzed the effects of 5-HT on the current flowing through KV channels (IK(V)) recorded in rat PASMC and through cloned hKV1.5 channels (IKV1.5) stably expressed in Ltk– cells. The role of 5-HT receptors and 5-HTT in 5-HT-induced effects has also been studied.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
All experiments were performed in accordance with the European Animals Act 1986 (Scientific Procedures) and approved by our institutional review board. A detailed description of the experimental methods is available in the online data supplement at http://circres.ahajournals.org.
Second- to third-order branches of the PA isolated from male Wistar rats were dissected and denuded of endothelium and PASMC were enzymatically isolated. Membrane currents were recorded in PASMC or in Ltk– cells stably expressing hKV1.5 channels using the whole-cell configuration of the patch-clamp technique and membrane potential was measured under current-clamp configuration.19,27 Coimmunoprecipitation, confocal immunostaining, and contractile tension studies are described in the online data supplement.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Effects of 5-HT on IK(V) and Membrane Potential in PASMC
Addition of 5-HT (10 µmol/L) markedly inhibited IK(V) at all potentials tested (Figure 1A and 1B) and depolarized PASMC (Figure 1D) (P<0.01). The concentration-response curve for the inhibition of IK(V) by 5-HT at test potentials of –30 and +60 mV was fitted to a Hill equation leading to Emax values of 41.2±3.4% and 50.2±0.5% and EC50 of 1.23±0.42 and 2.33±0.09 µmol/L, respectively (Figure 1C), indicating a voltage-independent inhibition. KV currents recorded before and after treatment with 5-HT showed similar activation kinetics and voltage-activation curves (supplemental Figure I). After washing with 5-HT-free solution for 10 to 15 minutes, the effects of 5-HT on KV currents (n=5; not shown) or on membrane potential (Figure 1D; n=3) were only weakly or not reversed. In contrast, the effects of the KV channel blocker 4-aminopyridine (4-AP) (3 mmol/L) on KV currents (not shown; n=3) or on membrane potential were reversed by
80% following a 5 minutes washing period (Figure 1E; n=3).
|
To test the involvement of 5-HT2A receptor on the IK(V) blocking properties of 5-HT, we performed experiments in the presence of the selective 5-HT2A receptor antagonist ketanserin (0.1 µmol/L). This drug had negligible effects on IK(V) but inhibited the effects of 5-HT on IK(V) (Figure 2) and on membrane potential (–46.3±2.1 and –45.2±2.1 before and after 5-HT, respectively; n=4). Similarly, the inhibitory effect of 5-HT on IK(V) was markedly attenuated in the presence of the 5-HTT inhibitor fluoxetine (0.1 µmol/L, Figure 2C; current-voltage [I-V] relationship in supplemental Figure II). However, other specific 5-HTT inhibitors such as fluvoxamine or citalopram or the 5-HT1B antagonist SB224289 (3 µmol/L) had no effects on the IK(V) blocking properties of 5-HT (Figure 2C; I-V relationships in supplemental Figure II).
|
Inhibition of hKV1.5 Currents by 5-HT
Figure 3 shows hKV1.5 current traces recorded in Ltk– cells stably expressing hKV1.5 channels. 5-HT (10 µmol/L) markedly inhibited hKV1.5 currents to a similar extent at all potentials tested, this effect being essentially prevented by ketanserin (0.1 µmol/L).
|
Role of Phospholipase C and Protein Kinases
To further assess the mechanisms involved in 5-HT-induced inhibition of IK(V), PASMC were perfused with different inhibitors before and during the addition of the agonist (summarized in Figure 4; I-V relationships in supplemental Figure III). The phospholipase C (PLC) inhibitor U73122 (3 µmol/L) and the classic protein kinase C (PKC) inhibitor Gö6976 (0.1 µmol/L) prevented the inhibitory effects of 5-HT on KV currents, whereas the PKC
pseudosubstrate inhibitor (PKC-PI) (0.1 µmol/L, added in the internal solution) had no effect. The tyrosine kinases inhibitor genistein (10 µmol/L) per se caused a 25% inhibition of IK(V) and prevented the effects of 5-HT on the current. The inhibitory effect of genistein on IK(V) has been previously reported and seems to be independent of its tyrosine kinase inhibition activity.28 In the presence of the more selective tyrosine kinase inhibitor tyrphostin 23 (30 µmol/L), which had no effect per se, the effects of 5-HT on IK(V) were inhibited (Figure 4B and 4C). Likewise, tyrphostin 23 prevented the inhibitory effects of 5-HT on hKV1.5 recorded in Ltk– cells (Figure 4D). Furthermore, the incubation with the tyrosine phosphatase inhibitor vanadate (100 µmol/L) increased the inhibitory effect of a low concentration of 5-HT (0.1 µmol/L) on IK(V) in PASMC (Figure 4E). Taken together, these results indicated the involvement of tyrosine kinases in the electrophysiological effects of 5-HT. However, we did not find changes in the KV1.5 protein phosphorylation in tyrosine or serine residues, whereas at least 2 bands with a molecular mass of 20 to 24 kDa that coimmunoprecipitated with KV1.5 proteins showed increased tyrosine phosphorylation after 5 minutes of treatment with 5-HT (Figure 4F). Their nature is presently unknown.
|
KV1.5 Association With 5-HT2A Receptors and Caveolin-1
Homogenates from PA were immunoprecipitated with anti-KV1.5 antibodies and analyzed for 5-HT2A receptors and caveolin-1 content via Western blot analysis. Figure 5A shows that both proteins coimmunoprecipitated with KV1.5. Furthermore, the interaction among KV1.5, caveolin-1, and 5-HT2A augmented after stimulation with 5-HT. To analyze the potential functional role of caveolae, PASMC were incubated with ß-cyclodextrin (2% for 2 hours), a cholesterol-modifying agent that disrupts membrane lipid rafts. Interestingly, 5-HT failed to inhibit IK(V) in these lipid raft-disrupted myocytes (Figure 5B and 5C). In addition, concanavalin A, a widely used inhibitor of endocytotic processes, had no effect on IK(V) but prevented the effects of 5-HT on IK(V) (Figure 5D). Finally, confocal microscopy revealed that KV1.5 channels were localized preferentially in the plasma membrane of PASMC but were partly internalized on 5-HT stimulation, and this effect was prevented with concanavalin A (Figure 5E).
|
Contractile Responses to 5-HT
Stimulation of endothelium-denuded PA rings with 5-HT (10 µmol/L) induced a sustained contractile response of 113±6 mg (n=47). Under control conditions, the contraction elicited by 5-HT was suitably reproduced after a 30 minute washout (99±6% of the first contraction, P>0.05). Pretreatment with 0.1 µmol/L ketanserin or 3 µmol/L SB224289 before the second addition of 5-HT inhibited the vasoconstriction (Figure 6A). Fluoxetine, but not the other 5-HTT inhibitors fluvoxamine and citalopram, also caused a marked inhibition of the vasoconstriction induced by 5-HT. Furthermore, the contraction induced by 5-HT was markedly inhibited by the L-type Ca2+ channel blocker nifedipine (0.1 µmol/L), the classic PKC inhibitor Gö6976 (0.1 µmol/L), the tyrosine kinases inhibitors genistein (10 µmol/L) or tyrphostin 23 (30 µmol/L), or the endocytosis inhibitor concanavalin A (250 µg/mL, Figure 6B). In PA contracted with 5-HT (10 µmol/L), addition of tyrphostin 23 (10 µmol/L) induced a relaxant response of 38±8% (n=5; Figure 6C). However, when arteries were stimulated by 5-HT plus the KV channel inhibitor 4-AP (10 mmol/L), tyrphostin 23 had no relaxant effect (1±1%, n=4; P<0.05).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This is the first study demonstrating regulation of the native PA KV channels and cloned human hKV1.5 channels by 5-HT. The main findings of the study can be summarized as follows. 5-HT depolarized PASMC and inhibited the KV current in PASMC and in Ltk– cells expressing cloned hKV1.5 but did not modify the activation curve and the kinetics of the currents. These effects were inhibited by antagonists/inhibitors of 5-HT2A receptors, PLC, classic PKCs, and tyrosine kinases and by cyclodextrin and concanavalin A. In addition, 5-HT2A receptors and caveolin-1 coimmunoprecipitated with KV1.5 channels, and KV1.5 channels internalized when cells were stimulated with 5-HT. Finally, the contraction induced by 5-HT in isolated rat PA was inhibited by the same drugs preventing KV channels inhibition.
Decreased KV channel activity leads to depolarization, opening of L-type voltage-dependent Ca2+ channels, increased [Ca2+]i, and vasoconstriction.16–18 Thus, KV channel blockers such as 4-AP induce depolarization and pulmonary vasoconstriction. In the present report, 5-HT caused KV current inhibition with a similar potency (EC50 values of 2 µmol/L) than that previously reported for pulmonary vasoconstriction (EC50 values of 1 and 3 µmol/L in fawn-hooded and Sprague-Dawley rats, respectively29) and with a similar or higher efficacy (50% inhibition) than other vasoactive factors known to inhibit KV channels such as endothelin-1 (29%20), the thromboxane A2 analog U46619 (56%19), or hypoxia (49%30). In addition, 5-HT caused membrane depolarization; its vasoconstrictor response was inhibited by the L-type Ca2+ channel blocker nifedipine and by the same drugs preventing KV channel inhibition. Furthermore, in 5-HT-contracted PA, the relaxation induced by the tyrosine kinase inhibitor tyrphostin 23 was abolished by 4-AP. All of these results are consistent with the view that 5-HT-induced vasoconstriction is, at least in part, mediated by KV channel inhibition. Accordingly, 5-HT has been previously reported to block KV channels in carotid body type I cells31 and in choroid plexus epithelial cells.32
As outlined in the introduction, multiple evidences indicate that 5-HT plays a key role in the pathogenesis of PH. However, the molecular target of 5-HT is not clearly defined, and it seems likely that several G protein-coupled receptors, as well as the 5-HTT, are involved in PH. 5-HT-induced pulmonary vasoconstriction seems to be mainly attributable to the activation of 5-HT2A and 5-HT1B/1D receptors.4,29 In the present study, 5-HT-induced vasoconstriction was inhibited by the selective antagonists of 5-HT2A and 5-HT1B receptors ketanserin and SB224289, respectively, whereas the inhibition of KV currents was prevented only by ketanserin. Therefore, 5-HT-induced vasoconstriction was mediated by at least 2 types of receptors, 5-HT2A and 5-HT1B, but only the former signaled via KV channels. The 5-HTT inhibitor fluoxetine also inhibited the effects of 5-HT on KV currents and vasoconstriction. In contrast, other selective 5-HTT inhibitors such as fluvoxamine and citalopram at concentrations sufficient to fully inhibit the transporter had no effect. The different behavior of fluoxetine suggests that this drug is acting via a 5-HTT-independent mechanism. In fact, fluoxetine inhibited (+)-norfenfluramine- and 5-HT-induced vasoconstriction in mice lacking 5-HTT.33 One possibility is that fluoxetine antagonized 5-HT2A receptors, because this drug, in contrast to the other 5-HTT inhibitors tested, has a relatively high affinity against the 5-HT2A receptor (Ki140 nmol/L).34 This drug, 1 of the most widely prescribed antidepressant, has been recently proposed as a novel treatment for PH.13 Its inhibitory effect on 5-HT-induced KV current attenuation described herein might contribute to its ability to prevent and reverse PH.
KV channels exist as tetramers formed by 4 transmembrane KV
subunits35 combined with modulatory cytosolic KVß subunits. In human PA, 22 transcripts of KV (KV1.1 to -1.7, KV1.10, KV2.1, KV3.1, KV3.3, KV3.4, KV4.1, KV4.2, KV5.1, KV6.1 to -6.3, KV9.1, KV9.3, KV10.1, and KV11.1), and 3 of KVß subunits (KVß1 to -3) have been identified by RT-PCR.36 Further diversity can be found in native channels because heterotetramers can be formed by the combination of distinct KV subunits. Because KV1.5 subunits are believed to be major contributors of the native KV currents in PA,16 we analyzed the effects of 5-HT on the KV current carried by human cloned KV1.5 channels expressed in Ltk– cells. 5-HT induced an inhibitory effect on this current of similar characteristics of that in native PA myocytes. This effect was also prevented by ketanserin and tyrphostin 23, suggesting a similar signaling pathway in both types of cells. In addition, we found a strong expression of 5-HT2A receptors by Western blot in Ltk– cells (not shown). Thus, KV1.5 channels are likely candidates to underlie 5-HT-sensitive currents in native cells, even when we cannot rule out that other KV channel subunits might also contribute to the effects of 5-HT.
In previous studies,19,27 we reported that KV channel inhibition induced by the thromboxane A2 analog U46619 in both rat and porcine PA, involved the activation of PKC, an atypical PKC that is insensitive to diacylglycerol. However, 5-HT-induced inhibition of KV current was not significantly affected by the specific PKC inhibitor. 5-HT2A receptors signal primarily through heterotrimeric proteins of the Gq/11 subfamily, activation of PLC, the subsequent formation of diacylglycerol, and activation of classic diacylglycerol-sensitive PKC.37 Likewise, the effects of 5-HT on KV currents were prevented by U73122, a PLC inhibitor, and by Gö6976, an inhibitor of classic diacylglycerol-sensitive PKCs, that does not inhibit PKC and did not modify the effects of U46619 in rat PA.19 Accordingly, KV channel inhibition by 5-HT in carotid body type I cells and rat choroid plexus epithelial cells was sensitive to PKC inhibitors.31,32 In addition, 5-HT-induced (but not U46619-induced) inhibition was prevented by genistein, a widely used tyrosine kinase inhibitor, and by tyrphostin 23, a selective tyrosine kinase inhibitor. Furthermore, PA contracted by 5-HT attained a relaxant response on treatment with tyrphostin 23, suggesting that tyrosine kinase(s) is a significant player in the response to 5-HT. Incubation with the KV channel blocker 4-AP before application of tyrphostin 23 completely blocked its relaxing effect, strongly supporting the idea that KV channels are coupled to tyrosine kinase activation after 5-HT receptor stimulation. Because the degree of phosphorylation of tyrosine residues results from the balance of the phosphorylating activity of tyrosine kinases and the dephosphorylating activity of tyrosine phosphatases, it is expected that inhibition of the latter may result in an enhancement of tyrosine kinase mediated effects. In fact, the tyrosine phosphatase inhibitor vanadate potentiated the inhibitory effects of low concentrations of 5-HT on KV currents. We found no changes at the level of tyrosine or serine phosphorylation in KV1.5 channel protein from cells incubated with 5-HT, ruling out a direct phosphorylation of KV1.5 subunits. However, we found that 5-HT induced tyrosine phosphorylation in at least 2 unknown proteins (molecular mass of 20 to 24 kDa), which coimmunoprecipitated with KV1.5. Taken together, these results suggest that activation of PLC, classic PKC, and tyrosine kinases are involved in the signaling pathway of 5-HT. Likewise, 5-HT2A receptors have been coupled with activation of tyrosine kinases including Src and JAK2 via PKC-dependent or -independent pathways.38,39
Caveolae are specialized microdomains in the plasma membrane composed of integral membrane proteins, including the protein caveolin-1, that are involved in endocytotic and signal-transduction processes.40 Caveolae serve to compartmentalize and integrate numerous signaling events, such as PKC, tyrosine kinases, mitogen-activated protein kinase, ion channels, G proteins, and G protein-coupled receptors.40 Caveolin has been reported to colocalize with KV1.5 channels on the membrane of transfected Ltk– cells41 and with 5-HT2A receptors on the membrane of transfected HEK-293 cells and C6 glioma cells.42 We found that KV1.5 coimmunoprecipitated with 5-HT2A receptors and caveolin-1 in native PA. Therefore, this association could serve to cluster the 5-HT2A receptor and signaling proteins with the K+ channel, allowing for specific modulation while preventing crosstalk with other pathways. Depletion of membrane cholesterol disrupts caveolar lipid rafts without changing the amplitude of KV1.5 currents.41 We found that lipid raft disruption with cyclodextrin prevented the inhibitory effects of 5-HT on KV currents, indicating the functional importance of this compartmentalization. Concanavalin A binds to cell surface glycoproteins and impairs their mobility within the membrane bilayer and is widely used to block endocytotic processes,43 including 5-HT2A receptor endocytosis in HEK-293 cells.44 In the present study, concanavalin A prevented the inhibitory effects on KV currents and the vasoconstriction induced by 5-HT. Likewise, endocytosis of KV1.2 and KV1.5 channels has been reported to be a key mechanism in the control of KV channel activity, which is regulated by tyrosine kinases.45,46 Confocal images of PASMC also showed that KV1.5 immunofluorescence changed from a preferential membrane to cytosolic localization on stimulation with 5-HT, and this effect was prevented by concanavalin A. Taken together, these results suggest that the 5-HT-induced inhibition of KV currents and the subsequent vasoconstriction of PA result from the interaction of 5-HT2A receptors with KV channels within caveolar membrane microdomains and involve tyrosine phosphorylation and endocytotic processes. This is consistent with a reduction in KV current amplitude without modification of its biophysical features.
PH has a multifactorial origin2,47 characterized by sustained elevation of pulmonary arterial pressure associated with vasoconstriction and PA smooth muscle proliferation. Both 5-HT and KV channels have been implicated in the pathogenesis of PH. In the present study, we demonstrate that there is a link between these 2 key pathogenetic factors. Thus, 5-HT, via activation of 5-HT2A receptors, inhibited the activity of KV channels, resulting in pulmonary vasoconstriction. Decreased KV channel activity not only causes pulmonary vasoconstriction but also contributes to pulmonary vascular medial hypertrophy by inhibiting apoptotic cell shrinkage and apoptosis,25 whereas overexpression of the KV1.5 gene (KCNA5) induces apoptosis in PASMC.48 Thus, KV channel inhibition might also be involved in the medial hypertrophy of PA induced by 5-HT.5,49 Additionally, it must be noted that KV channel blockade has also been involved in the vasoconstriction and pulmonary hypertension induced by anorexigens and the antiparkinsonian drug pergolide.21,50 Interestingly, dexfenfluramine and pergolide activate 5-HT2A receptors,34,51 which suggests that KV channel blockade induced by these drugs might be secondary to 5-HT2A receptor activation.
In conclusion, 5-HT inhibits KV currents in PA myocytes and in Ltk– cells stably transfected with human KV1.5 channels through the activation of 5-HT2A receptors, PLC, classic PKCs, tyrosine kinases, and endocytotic processes. This effect is involved, at least partly, in PA vasoconstriction and might contribute to the development of human PH.
|
Acknowledgments |
|---|
This work was supported by grants from the Comisión Interministerial de Ciencia y Tecnología (SAF2005-03770, SAF2005-04609, and AGL2004-06685-C04-1) and from Comunidad Autónoma de Madrid (GR/SAL/0594/2004). A.C, L.M., and F.L. are supported by RECAVA (Red Temática de Investigación Cardiovascular), Ministerio de Educación y Ciencia (FPU), and CSIC (I3P grant), respectively.
|
Footnotes |
|---|
Original received October 19, 2005; revision received February 22, 2006; accepted February 28, 2006.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol. 2000; 131: 161–168.[CrossRef][Medline] [Order article via Infotrieve]
2. Yuan JX-J, Rubin LJ. Pathogenesis of pulmonary arterial hypertension. Circulation. 2005; 111: 534–538.
3. Launay JM, Herve P, Peoc’h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002; 8: 1129–1135.[CrossRef][Medline] [Order article via Infotrieve]
4. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol. 1996; 119: 917–930.[Medline] [Order article via Infotrieve]
5. Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G, Hamon M, Adnot S, Eddahibi S. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 2004; 94: 1263–1270.
6. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995; 99: 249–254.[CrossRef][Medline] [Order article via Infotrieve]
7. Tornebrandt K, Eskilsson J, Nobin A. Heart involvement in metastatic carcinoid disease. Clin Cardiol. 1986; 9: 13–19.[Medline] [Order article via Infotrieve]
8. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 335: 609–616.
9. Eddahibi S, Chaouat A, Morrell N, Fadel E, Furham C, Bugnet A-S, Dartevelle P, Housset B, Hamon M, Weitzenblum E, Adnot S. Polymorphism of the SERT gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 2003; 108: 1839–1844.
10. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001; 108: 1141–1150.[CrossRef][Medline] [Order article via Infotrieve]
11. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000; 105: 1555–1562.[Medline] [Order article via Infotrieve]
12. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res. 2001; 89: 1231–1239.
13. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005; 111: 2812–2819.
14. Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, Yamazaki A, Ushiyama Y, Yazaki Y, Kinoshita O. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res. 2003; 60: 692–699.
15. Miyata M, Ito M, Sasajima T, Ohira H, Sato Y, Kasukawa R. Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. Lung. 2000; 178: 63–73.[CrossRef][Medline] [Order article via Infotrieve]
16. Archer S, Souil E, Dinh-Xuan AT, Schremmer B, Mercier JC, El Yaagoubi A, Nguyen-Huu L, Reeve HL, Hampl V. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv1.2, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest. 1998; 101: 2319–2330.[Medline] [Order article via Infotrieve]
17. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol. 1995; 268: C799–C822.[Medline] [Order article via Infotrieve]
18. Yuan X-J. Voltage-gated K+ currents regulate resting membrane potential and [Ca2+]i in pulmonary arterial myocytes. Circ Res. 1995; 77: 370–378.
19. Cogolludo A, Moreno L, Boscá L, Tamargo J, Pérez-Vizcaino F. Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction. Role of protein kinase C. Circ Res. 2003; 93: 656–663.
20. Shimoda LA, Sylvester JT, Sham JS. Inhibition of voltage-gated K+ current in intrapulmonary arterial myocytes by endothelin-1. Am J Physiol. 1998; 274: L842–L853.[Medline] [Order article via Infotrieve]
21. Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, Archer SL. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996; 94: 2216–2220.
22. Yuan X-J, Wang J, Juhaszova M, Gaine SP, Rubin L. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet. 1998; 351: 726–727.[CrossRef][Medline] [Order article via Infotrieve]
23. Remillard CV, Tigno DD, Rana BK, Conger D, Nicholson A, Rubin LJ, O’Connor DT, Yuan JX. Novel SNPs in KCNA5 gene from patients with idiopathic pulmonary hypertension. Circulation. 2004; 110 (suppl III): III-20 Abstract.
24. Pozeg ZI, Michelakis ED, McMurtry MS, Thebaud B, Wu XC, Dyck JR, Hashimoto K, Wang S, Moudgil R, Harry G, Sultanian R, Koshal A, Archer SL. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation. 2003; 107: 2037–2044.
25. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ, and Yuan JX-J. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003; 285: L740–L754.
26. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004; 95: 830–840.
27. Cogolludo A, Moreno L, Lodi F, Tamargo J, Perez-Vizcaino F. Postnatal maturational shift from PKC and voltage-gated K+ channels to RhoA/Rho kinase in pulmonary vasoconstriction. Cardiovasc Res. 2005; 66: 84–93.
28. Smirnov SV, Aaronson PI. Inhibition of vascular smooth muscle cell K+ currents by tyrosine kinase inhibitors genistein and ST638. Circ Res. 1995; 76: 310–316.
29. Morecroft I, Loughlin L, Nilsen M, Colston J, Dempsie Y, Sheward J, Harmar A, MacLean MR. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther. 2005; 313: 539–548.
30. Archer SL, Wu XC, Thebaud B, Nsair A, Bonnet S, Tyrrell B, McMurtry MS, Hashimoto K, Harry G, Michelakis ED. Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circ Res. 2004; 95: 308–318.
31. Zhang M, Fearon IM, Zhong H, Nurse CA. Presynaptic modulation of rat arterial chemoreceptor function by 5-HT: role of K+ channel inhibition via protein kinase C. J Physiol. 2003; 551: 825–842.
32. Speake T, Kibble JD, Brown PD. Kv1.1 and Kv1.3 channels contribute to the delayed-rectifying K+ conductance in rat choroid plexus epithelial cells. Am J Physiol Cell Physiol. 2004; 286: C611–C620.
33. Ni W, Wilhelm CS, Bader M, Murphy DL, Lookingland KJ, Watts SW. (+)-Norfenfluramine-induced arterial contraction is not dependent on endogenous 5-HT or 5-HTT. J Pharmacol Exp Ther. 2005; 314: 953–960.
34. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997; 283: 1305–1322.
35. MacKinnon R. Determination of the subunit stoichiometry of a voltage-activated potassium channel. Nature. 1991; 350: 232–235.[CrossRef][Medline] [Order article via Infotrieve]
36. Platoshyn O, Remillard CV, Fantozzi I, Mandegar M, Sison TT, Zhang S, Burg E, Yuan JX. Diversity of voltage-dependent K+ channels in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2004; 287: L226–L238.
37. Tamir H, Hsiung SC, Yu PY, Liu KP, Adlersberg M, Nunez EA, Gershon MD. Serotonergic signalling between thyroid cells: protein kinase C and 5-HT2 receptors in the secretion and action of serotonin. Synapse. 1992; 12: 155–168.[CrossRef][Medline] [Order article via Infotrieve]
38. Banes AK, Shaw SM, Tawfik A, Patel BP, Ogbi S, Fulton D, Marrero MB. Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. Am J Physiol Cell Physiol. 2005; 288: C805–C812.
39. Quinn JC, Johnson-Farley NN, Yoon J, Cowen DS. Activation of extracellular-regulated kinase by 5-hydroxytryptamine(2A) receptors in PC12 cells is protein kinase C-independent and requires calmodulin and tyrosine kinases. J Pharmacol Exp Ther. 2002; 303: 746–752.
40. Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol. 1998; 275: L843–L851.[Medline] [Order article via Infotrieve]
41. Martens JR, Sakamoto N, Sullivan SA, Grobaski TD, Tamkun MM. Isoform-specific localization of voltage-gated K+ channels to distinct lipid raft populations. Targeting of Kv1.5 to caveolae. J Biol Chem. 2001; 276: 8409–8414.
42. Bhatnagar A, Sheffler DJ, Kroeze WK, Compton-Toth B, Roth BL. Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J Biol Chem. 2004; 279: 34614–34623.
43. Luttrell LM, Daaka Y, Della Rocca GJ, Lefkowitz RJ. G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts. Shc phosphorylation and receptor endocytosis correlate with activation or Erk kinases. J Biol Chem. 1997; 272: 31648–31656.
44. Gray JA, Sheffler DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL, Roth BL. Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells. Mol Pharmacol. 2001; 60: 1020–1030.
45. Nesti E, Everill B, Morielli AD. Endocytosis as a mechanism for tyrosine kinase-dependent suppression of a voltage-gated potassium channel. Mol Biol Cell. 2004; 15: 4073–4088.
46. Choi WS, Khurana A, Mathur R, Viswanathan V, Steele DF, Fedida D. Kv1.5 surface expression is modulated by retrograde trafficking of newly endocytosed channels by the dynein motor. Circ Res. 2005; 97: 363–371.
47. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43 (12 suppl S): 13S–24S.
48. Brevnova EE, Platoshyn O, Zhang S, Yuan JX. Overexpression of human KCNA5 increases IKV and enhances apoptosis. Am J Physiol Cell Physiol. 2004; 287: C715–C722.
49. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res. 2004; 68: 75–103.[CrossRef][Medline] [Order article via Infotrieve]
50. Hong Z, Smith AJ, Archer SL, Wu XC, Nelson DP, Peterson D, Johnson G, Weir EK. Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation. 2005; 112: 1494–1499.
51. Kren V, Eich E, Pertz HH. Pergolide, terguride and N,N'-spacer-linked oligomers of both interact with 5-HT2A receptors of rat tail artery. Physiol Res. 2004; 53: 35–43.[Medline] [Order article via Infotrieve]
Related Article:
Circ. Res. 2006 98: 860-862.
This article has been cited by other articles:
 |
|
 |
|
  A. L. Cogolludo, J. Moral-Sanz, S. van der Sterren, G. Frazziano, A. N. H. van Cleef, C. Menendez, B. Zoer, E. Moreno, A. Roman, F. Perez-Vizcaino, et al. Maturation of O2 sensing and signaling in the chicken ductus arteriosus Am J Physiol Lung Cell Mol Physiol, October 1, 2009; 297(4): L619 - L630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Idkowiak-Baldys, A. Baldys, J. R. Raymond, and Y. A. Hannun Sustained Receptor Stimulation Leads to Sequestration of Recycling Endosomes in a Classical Protein Kinase C- and Phospholipase D-dependent Manner J. Biol. Chem., August 14, 2009; 284(33): 22322 - 22331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Rainbow, R. I. Norman, D. E. Everitt, J. L. Brignell, N. W. Davies, and N. B. Standen Endothelin-I and angiotensin II inhibit arterial voltage-gated K+ channels through different protein kinase C isoenzymes Cardiovasc Res, August 1, 2009; 83(3): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. W. Morrell, S. Adnot, S. L. Archer, J. Dupuis, P. Lloyd Jones, M. R. MacLean, I. F. McMurtry, K. R. Stenmark, P. A. Thistlethwaite, N. Weissmann, et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S20 - S31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cogolludo, L. Moreno, G. Frazziano, J. Moral-Sanz, C. Menendez, J. Castaneda, C. Gonzalez, E. Villamor, and F. Perez-Vizcaino Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction Cardiovasc Res, May 1, 2009; 82(2): 296 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Luykenaar, R. A. El-Rahman, M. P. Walsh, and D. G. Welsh Rho-kinase-mediated suppression of KDR current in cerebral arteries requires an intact actin cytoskeleton Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H917 - H926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Lopez-Lopez, J. Moral-Sanz, G. Frazziano, M. J. Gomez-Villalobos, J. Flores-Hernandez, E. Monjaraz, A. Cogolludo, and F. Perez-Vizcaino Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction Am J Physiol Lung Cell Mol Physiol, November 1, 2008; 295(5): L727 - L732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vicente, N. Villalonga, M. Calvo, A. Escalada, C. Solsona, C. Soler, M. M. Tamkun, and A. Felipe Kv1.5 Association Modifies Kv1.3 Traffic and Membrane Localization J. Biol. Chem., March 28, 2008; 283(13): 8756 - 8764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. McEwen, Q. Li, S. Jackson, P. M. Jenkins, and J. R. Martens Caveolin Regulates Kv1.5 Trafficking to Cholesterol-Rich Membrane Microdomains Mol. Pharmacol., March 1, 2008; 73(3): 678 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Weir, M. Obreztchikova, and Z. Hong Fenfluramine: riddle or Rosetta stone? Eur. Respir. J., February 1, 2008; 31(2): 232 - 235. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Archer, M. Gomberg-Maitland, M. L. Maitland, S. Rich, J. G. N. Garcia, and E. K. Weir Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1{alpha}-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H570 - H578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Moreno, G. Frazziano, A. Cogolludo, L. Cobeno, J. Tamargo, and F. Perez-Vizcaino Role of Protein Kinase C{zeta} and Its Adaptor Protein p62 in Voltage-Gated Potassium Channel Modulation in Pulmonary Arteries Mol. Pharmacol., November 1, 2007; 72(5): 1301 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Koide, P. L. Penar, B. I. Tranmer, and G. C. Wellman Heparin-binding EGF-like growth factor mediates oxyhemoglobin-induced suppression of voltage-dependent potassium channels in rabbit cerebral artery myocytes Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1750 - H1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Sehgal and S. Mukhopadhyay Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs? Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H77 - H85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanchez, F. Lodi, R. Vera, I. C. Villar, A. Cogolludo, R. Jimenez, L. Moreno, M. Romero, J. Tamargo, F. Perez-Vizcaino, et al. Quercetin and Isorhamnetin Prevent Endothelial Dysfunction, Superoxide Production, and Overexpression of p47phox Induced by Angiotensin II in Rat Aorta J. Nutr., April 1, 2007; 137(4): 910 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Caestecker Serotonin Signaling in Pulmonary Hypertension Circ. Res., May 26, 2006; 98(10): 1229 - 1231. [Full Text] [PDF]
|
|
|
|
|
|
A. Varghese, Z. Hong, and E. K. Weir Serotonin-Induced Inhibition of KV Current: A Supporting Role in Pulmonary Vasoconstriction? Circ. Res., April 14, 2006; 98(7): 860 - 862. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||